Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





Semperit AG Holding / Group interim report for 3rd quarter shows significant EBITDA improvement – EBIT and earnings after tax are negative after one-off effects in Medical Sector

APA-OTS-Meldungen aus dem Finanzsektor in der "BSN Extended Version"
Wichtige Originaltextaussendungen aus der Branche. Wir ergänzen vollautomatisch Bilder aus dem Fundus von photaq.com und Aktieninformationen aus dem Börse Social Network. Wer eine Korrektur zu den Beiträgen wünscht: mailto:office@boerse-social.com . Wir wiederum übernehmen keinerlei Haftung für Augenerkrankungen aufgrund von geballtem Grossbuchstabeneinsatz der Aussender. Wir meinen: Firmennamen, die länger als drei Buchstaben sind, schreibt man nicht durchgängig in Grossbuchstaben (Versalien).
Magazine aktuell


#gabb aktuell



19.12.2019, 3907 Zeichen



Corporate news transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.
Quarterly Report
Vienna -
Group revenue decreased by 2.7% to EUR 652.2 million\nEBITDA increased to EUR 60.4 million (after one-off effect), EBITDA margin to 9.3%\nImpairment loss in Medical Sector: EUR 46.8 million\nGroup EBIT after impairment loss in Medical Sector at EUR -13.7 million, EBIT margin at -2.1%\nAdjusted EBIT at EUR 29.0 million, adjusted EBIT margin at 4.4%\nEarnings after tax: EUR -34.1 million, adjusted EUR 8.6 million\nVienna/Austria, 19 December 2019 - The publicly listed Semperit Group significantly improved the operating results with increasing profitability on EBITDA level in the first three quarters of 2019, while revenue declined slightly. In the first three quarters of 2019, total revenue recorded a year-on- year decline of 2.7% to EUR 652.2 million.
EBITDA rose from EUR 41.9 million in the first three quarters of 2018 to EUR 60.4 million in the first three quarters of 2019. Adjusted for the one-off effects, EBITDA rose from EUR 45.8 million in the past year(1) to EUR 56.4 million until the third quarter of 2019(2). The EBITDA margin rose from 6.3% to 9.3% in the first three quarters of 2019 and reflects the profitability improved by the restructuring and transformation process (adjusted: 8.6% versus 6.8% in the previous year). As a result, the aggregated value for 2018 was already exceeded at the end of the third quarter.
Due to current information on the competitive situation of the medical business, an impairment loss of EUR 46.8 million was recognized in the Medical Sector. The background to this is the investment intensity of the significant competitors, which increased beyond expectations through capacity expansion and production automation, and the highly dynamic development of the market environment. Despite Sempermed segment's progress regarding the improvement of operating results, which is quicker than planned, it is to be expected that overcapacities on the market and the resulting price pressure will affect the profitability in a significantly negative manner.
Group EBIT improved to EUR -13.7 million in the first three quarters of 2019 from EUR -45.5 million in the previous year. EBITDA margin was -2.1% after - 6.8%. Adjusted for one-off effects(3), EBIT amounted to EUR 29.0 million compared to EUR 17.5 million in the previous year. The adjusted EBIT margin improved to 4.4.% versus 2.6% in the comparable period in the previous year.
Earnings after tax improved in the first three quarters of 2019 to EUR -34.1 million compared to EUR -72.9 million for the first three quarters of 2018. Earnings per share amounted to EUR -1.66 compared with -3.68 in the same period of 2018. Adjusted for one-off effects, the earnings after tax amounted to EUR 8.6 million compared with EUR -9.9 million in the same period of the previous year.
1) Excluding the negative one-off effect of EUR 3.9 million from the closure of the Sempertrans site in China for the first three quarters of 2018 2) Excluding the positive one-off effect of EUR 4.0 million from the reversal of a provision for the tax proceedings on levies in Brazil 3) Q1-3 2019: reversal of a provision of EUR 4.0 million and impairment loss at Sempermed of EUR 46.8 million; Q1-3 2018: EUR 3.9 million from the closure of the Sempertrans site in China and impairment loss especially at Sempermed of EUR 55.2 million
end of announcement euro adhoc
issuer: Semperit AG Holding Modecenterstrasse 22 A-1030 Wien phone: +43 1 79 777-310 FAX: +43 1 79 777-602 mail: judit.helenyi@semperitgroup.com WWW: www.semperitgroup.com ISIN: AT0000785555 indexes: WBI, ATX PRIME, ATX GP stockmarkets: Wien language: English
Digital press kit: http://www.ots.at/pressemappe/2918/aom

BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #636: Marcel Hirscher läutet wieder die Opening Bell und ich denke dabei an Palfinger und Raiffeisen




Semperit
Akt. Indikation:  11.74 / 11.90
Uhrzeit:  23:00:16
Veränderung zu letztem SK:  0.17%
Letzter SK:  11.80 ( -0.84%)



 

Bildnachweis

1. Markus Keller ist seit April 2017 Leiter des Segments Sempertrans; Bild: Semperit , (© Aussendung)   >> Öffnen auf photaq.com

Aktien auf dem Radar:Addiko Bank, Immofinanz, Marinomed Biotech, Flughafen Wien, Warimpex, EuroTeleSites AG, ATX Prime, ams-Osram, AT&S, Palfinger, RBI, Strabag, Pierer Mobility, UBM, CA Immo, Frequentis, Lenzing, SW Umwelttechnik, Oberbank AG Stamm, Wolford, Agrana, Amag, Erste Group, EVN, Kapsch TrafficCom, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, Wienerberger.


Random Partner

Croma
Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Mehr aktuelle OTS-Meldungen HIER

Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten


Meistgelesen
>> mehr





PIR-Zeichnungsprodukte
AT0000A39G83
AT0000A39UT1
AT0000A347X9
Newsflow
>> mehr

Börse Social Club Board
>> mehr
    wikifolio-Trades Austro-Aktien 22-23: Fabasoft(1)
    wikifolio-Trades Austro-Aktien 20-21: Bawag(1)
    wikifolio-Trades Austro-Aktien 19-20: Andritz(1), Uniqa(1), AT&S(1)
    wikifolio-Trades Austro-Aktien 18-19: Semperit(1), ams-Osram(1)
    Star der Stunde: EVN 1.18%, Rutsch der Stunde: Warimpex -3.6%
    Star der Stunde: Pierer Mobility 1.58%, Rutsch der Stunde: Warimpex -3.6%
    wikifolio-Trades Austro-Aktien 16-17: Kontron(1)
    Star der Stunde: Strabag 2%, Rutsch der Stunde: Warimpex -3.6%
    wikifolio-Trades Austro-Aktien 15-16: Kontron(3), Bawag(1), ams-Osram(1)

    Featured Partner Video

    Ein Tausender ist nix!

    Das Sporttagebuch mit Michael Knöppel - 11. April 2024 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
    Das Sporttagebuch mit Michael Knöppel - 11....

    Books josefchladek.com

    Adrianna Ault
    Levee
    2023
    Void

    Christian Reister
    Driftwood 15 | New York
    2023
    Self published

    Sergio Castañeira
    Limbo
    2023
    ediciones anómalas

    Tommaso Protti
    Terra Vermelha
    2023
    Void

    François Jonquet
    Forage
    2023
    Void

    Semperit AG Holding / Group interim report for 3rd quarter shows significant EBITDA improvement – EBIT and earnings after tax are negative after one-off effects in Medical Sector


    19.12.2019, 3907 Zeichen

    Corporate news transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.
    Quarterly Report
    Vienna -
    Group revenue decreased by 2.7% to EUR 652.2 million\nEBITDA increased to EUR 60.4 million (after one-off effect), EBITDA margin to 9.3%\nImpairment loss in Medical Sector: EUR 46.8 million\nGroup EBIT after impairment loss in Medical Sector at EUR -13.7 million, EBIT margin at -2.1%\nAdjusted EBIT at EUR 29.0 million, adjusted EBIT margin at 4.4%\nEarnings after tax: EUR -34.1 million, adjusted EUR 8.6 million\nVienna/Austria, 19 December 2019 - The publicly listed Semperit Group significantly improved the operating results with increasing profitability on EBITDA level in the first three quarters of 2019, while revenue declined slightly. In the first three quarters of 2019, total revenue recorded a year-on- year decline of 2.7% to EUR 652.2 million.
    EBITDA rose from EUR 41.9 million in the first three quarters of 2018 to EUR 60.4 million in the first three quarters of 2019. Adjusted for the one-off effects, EBITDA rose from EUR 45.8 million in the past year(1) to EUR 56.4 million until the third quarter of 2019(2). The EBITDA margin rose from 6.3% to 9.3% in the first three quarters of 2019 and reflects the profitability improved by the restructuring and transformation process (adjusted: 8.6% versus 6.8% in the previous year). As a result, the aggregated value for 2018 was already exceeded at the end of the third quarter.
    Due to current information on the competitive situation of the medical business, an impairment loss of EUR 46.8 million was recognized in the Medical Sector. The background to this is the investment intensity of the significant competitors, which increased beyond expectations through capacity expansion and production automation, and the highly dynamic development of the market environment. Despite Sempermed segment's progress regarding the improvement of operating results, which is quicker than planned, it is to be expected that overcapacities on the market and the resulting price pressure will affect the profitability in a significantly negative manner.
    Group EBIT improved to EUR -13.7 million in the first three quarters of 2019 from EUR -45.5 million in the previous year. EBITDA margin was -2.1% after - 6.8%. Adjusted for one-off effects(3), EBIT amounted to EUR 29.0 million compared to EUR 17.5 million in the previous year. The adjusted EBIT margin improved to 4.4.% versus 2.6% in the comparable period in the previous year.
    Earnings after tax improved in the first three quarters of 2019 to EUR -34.1 million compared to EUR -72.9 million for the first three quarters of 2018. Earnings per share amounted to EUR -1.66 compared with -3.68 in the same period of 2018. Adjusted for one-off effects, the earnings after tax amounted to EUR 8.6 million compared with EUR -9.9 million in the same period of the previous year.
    1) Excluding the negative one-off effect of EUR 3.9 million from the closure of the Sempertrans site in China for the first three quarters of 2018 2) Excluding the positive one-off effect of EUR 4.0 million from the reversal of a provision for the tax proceedings on levies in Brazil 3) Q1-3 2019: reversal of a provision of EUR 4.0 million and impairment loss at Sempermed of EUR 46.8 million; Q1-3 2018: EUR 3.9 million from the closure of the Sempertrans site in China and impairment loss especially at Sempermed of EUR 55.2 million
    end of announcement euro adhoc
    issuer: Semperit AG Holding Modecenterstrasse 22 A-1030 Wien phone: +43 1 79 777-310 FAX: +43 1 79 777-602 mail: judit.helenyi@semperitgroup.com WWW: www.semperitgroup.com ISIN: AT0000785555 indexes: WBI, ATX PRIME, ATX GP stockmarkets: Wien language: English
    Digital press kit: http://www.ots.at/pressemappe/2918/aom

    BSN Podcasts
    Christian Drastil: Wiener Börse Plausch

    Wiener Börse Party #636: Marcel Hirscher läutet wieder die Opening Bell und ich denke dabei an Palfinger und Raiffeisen




    Semperit
    Akt. Indikation:  11.74 / 11.90
    Uhrzeit:  23:00:16
    Veränderung zu letztem SK:  0.17%
    Letzter SK:  11.80 ( -0.84%)



     

    Bildnachweis

    1. Markus Keller ist seit April 2017 Leiter des Segments Sempertrans; Bild: Semperit , (© Aussendung)   >> Öffnen auf photaq.com

    Aktien auf dem Radar:Addiko Bank, Immofinanz, Marinomed Biotech, Flughafen Wien, Warimpex, EuroTeleSites AG, ATX Prime, ams-Osram, AT&S, Palfinger, RBI, Strabag, Pierer Mobility, UBM, CA Immo, Frequentis, Lenzing, SW Umwelttechnik, Oberbank AG Stamm, Wolford, Agrana, Amag, Erste Group, EVN, Kapsch TrafficCom, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, Wienerberger.


    Random Partner

    Croma
    Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.

    >> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


    Mehr aktuelle OTS-Meldungen HIER

    Useletter

    Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

    Newsletter abonnieren

    Runplugged

    Infos über neue Financial Literacy Audio Files für die Runplugged App
    (kostenfrei downloaden über http://runplugged.com/spreadit)

    per Newsletter erhalten


    Meistgelesen
    >> mehr





    PIR-Zeichnungsprodukte
    AT0000A39G83
    AT0000A39UT1
    AT0000A347X9
    Newsflow
    >> mehr

    Börse Social Club Board
    >> mehr
      wikifolio-Trades Austro-Aktien 22-23: Fabasoft(1)
      wikifolio-Trades Austro-Aktien 20-21: Bawag(1)
      wikifolio-Trades Austro-Aktien 19-20: Andritz(1), Uniqa(1), AT&S(1)
      wikifolio-Trades Austro-Aktien 18-19: Semperit(1), ams-Osram(1)
      Star der Stunde: EVN 1.18%, Rutsch der Stunde: Warimpex -3.6%
      Star der Stunde: Pierer Mobility 1.58%, Rutsch der Stunde: Warimpex -3.6%
      wikifolio-Trades Austro-Aktien 16-17: Kontron(1)
      Star der Stunde: Strabag 2%, Rutsch der Stunde: Warimpex -3.6%
      wikifolio-Trades Austro-Aktien 15-16: Kontron(3), Bawag(1), ams-Osram(1)

      Featured Partner Video

      Ein Tausender ist nix!

      Das Sporttagebuch mit Michael Knöppel - 11. April 2024 E-Mail: sporttagebuch.michael@gmail.com Instagram: @das_sporttagebuch Twitter: @Sporttagebuch_
      Das Sporttagebuch mit Michael Knöppel - 11....

      Books josefchladek.com

      Robert Frank
      The Americans (fifth American edition)
      1978
      Aperture

      Federico Renzaglia
      Bonifica
      2024
      Self published

      Sebastián Bruno
      Ta-ra
      2023
      ediciones anómalas

      Valie Export
      Körpersplitter
      1980
      Veralg Droschl

      Martin Frey & Philipp Graf
      Spurensuche 2023
      2023
      Self published